Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13775444 | 0.92 | GAA (0.40) | KDM4ENPC1LMNARAB9ASMN1; SMN2 | |
| SCHEMBL4123566 | 0.92 | NR1H4 (0.36) | NFE2L2LMNASMN1; SMN2NR1H4GAA | |
| SCHEMBL4123573 | 0.92 | NR1H4 (0.36) | NFE2L2LMNASMN1; SMN2NR1H4GAA | |
| SCHEMBL13775456 | 0.91 | NR1H4 (0.37) | KDM4ENR1H4GAA | |
| SCHEMBL4122700 | 0.91 | NFE2L2 (0.38) | NFE2L2KDM4EALDH1A1GAA | |
| SCHEMBL4122696 | 0.91 | NFE2L2 (0.38) | NFE2L2KDM4EALDH1A1GAA | |
| SCHEMBL4123934 | 0.87 | GAA (0.51) | KDM4ENPC1ALDH1A1LMNARAB9A | |
| SCHEMBL13775726 | 0.87 | KRAS (0.37) | KDM4EALDH1A1LMNASMN1; SMN2NR1H4 | |
| SCHEMBL13775458 | 0.86 | PKM (0.41) | KDM4EALDH1A1SMN1; SMN2NR1H4 | |
| SCHEMBL4110749 | 0.86 | GAA (0.39) | GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090181942-A1 | TRICYCLIC COMPOUNDS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-07-16 | — | — | US | disclosed |
| EP-1939205-A1 | TRICYCLIC COMPOUND | Daiichi Sankyo Company, Limited (JP) | 2008-07-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181942-A1 | TRICYCLIC COMPOUNDS | FDFT1, COASY, HMGCR | NFE2L2 2491/4885KDM4E 2123/4885NPC1 187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.